Literature DB >> 28054479

Persistent risk for hepatocellular carcinoma after more than a decade of successful hepatitis B virus suppression.

Andrew Dargan1, She Y Wong1, Robert Coben1, Mitchell Conn1, Anthony J Dimarino1, Hie W Hann2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28054479     DOI： 10.23736/S1121-421X.16.02350-3

Source DB:  PubMed          Journal:  Minerva Gastroenterol Dietol        ISSN： 1121-421X


× No keyword cloud information.
  5 in total

Review 1.  Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure.

Authors:  Joseph Yoo; Hie-Won Hann; Robert Coben; Mitchell Conn; Anthony J DiMarino
Journal:  Diseases       Date:  2018-04-20

2.  Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas.

Authors:  Yanyan Wei; Yongxiang Yi; Chen Tao; Wei Ye; Wei Zhao
Journal:  Cancer Manag Res       Date:  2019-09-17       Impact factor: 3.989

Review 3.  Hepatitis B Virus-Associated Hepatocellular Carcinoma and Chronic Stress.

Authors:  Nicholas Noverati; Rukaiya Bashir-Hamidu; Dina Halegoua-DeMarzio; Hie-Won Hann
Journal:  Int J Mol Sci       Date:  2022-04-01       Impact factor: 5.923

Review 4.  The impact of antiviral therapy on hepatocellular carcinoma epidemiology.

Authors:  Massimo Colombo; Ana Lleo
Journal:  Hepat Oncol       Date:  2018-05-10

Review 5.  Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure.

Authors:  Brianna J Shinn; Aaron Martin; Robert M Coben; Mitchell I Conn; Jorge Prieto; Howard Kroop; Anthony J DiMarino; Hie-Won Hann
Journal:  World J Hepatol       Date:  2019-01-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.